Polymorphism in cytochrome P450 1A2 and their interaction with risk factors in determining risk of squamous cell lung carcinoma in men

Cancer Biomarkers

Volumn 8, Issue 6, 2010, Pages 351-359

  Singh, Arvind P ^b   Pant, Mohan C ^a   Ruwali, Munindra ^b   Shah, Parag P ^b   Prasad, Rajendra ^a   Mathur, Neeraj ^b   Parmar, Devendra ^b  

^a KING GEORGE'S MEDICAL UNIVERSITY   (India)

^b CSIR INDIAN INSTITUTE OF TOXICOLOGY RESEARCH   (India)

Author keywords

CYP1A2; Lung cancer; polymorphism; risk; tobacco

Indexed keywords

CYTOCHROME P450 1A2;

ADULT; ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; CONTROLLED STUDY; GENOTYPE; HAPLOTYPE; HUMAN; LUNG SQUAMOUS CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RISK FACTOR; SMOKING;

ADULT; ALLELES; CARCINOMA, SQUAMOUS CELL; CASE-CONTROL STUDIES; CYTOCHROME P-450 CYP1A2; GENE-ENVIRONMENT INTERACTION; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; RISK FACTORS;

NICOTIANA TABACUM;

EID: 80955139695     PISSN: 15740153     EISSN: 18758592     Source Type: Journal    
DOI: 10.3233/CBM-2011-0224     Document Type: Article

References (39)

1. A. Jemal, R. Siegel, J. Xu and E.Ward, Cancer statistics, 2010, CA Cancer J lin 60 (2010), 277-300.
2. IARC, Tobacco smoking, IARCmonographs on the evaluation of the carcinogenic risk of chemicals to humans, Lyon: IARC 38 (1986), 127-135.
3. S.S. Hecht, Tobacco smoke carcinogens and lung cancer, J Natl Cancer Inst 91 (1999), 1194-1210. (Pubitemid 29357186)
4. A.K. Hackshaw, M.R. Law and N.J. Wald, The accumulated evidence on lung cancer and environmental tobacco smoke, British Medical Journal 315 (1997), 980-988. (Pubitemid 27443125)
5. O.Y. Gorlova, S.F. Weng and Y. Zhang, Aggregation of cancer among relatives of never-smoking lung cancer patients, International Journal of Cancer 121 (2007), 111-118. (Pubitemid 46753858)
6. U. Nair and H. Bartsch, Metabolic polymorphisms as susceptibility markers for lung and oral cavity, IARC Sci Publ 154 (2001), 271-290.
7. H. Bartsch, U. Nair, A. Risch, M. Rojas, H. Wikman and K. Alexandrov, Genetic polymorphism of CYP genes, alone or in combination, as a risk modifier of tobacco-related cancers, Cancer Epidemiol Biomarkers Prev 9 (2000), 3-28. (Pubitemid 30062906)
8. A.P. Singh, P.P. Shah,M. Ruwali, N. Mathur,M.C. Pant and D. Parmar, Polymorphism in cytochrome P4501A1 is significantly associated with head and neck cancer risk, Cancer Invest 27 (2009), 869-876.
9. A.P. Singh, P.P. Shah, N.Mathur, J.T. Buters, M.C. Pant andD. Parmar, Genetic polymorphisms in cytochrome P4501B1 and susceptibility to head and neck cancer, Mutat Res 639 (2008), 11-19.
10. M. Singh, P.P. Shah, A.P. Singh, M. Ruwali, N. Mathur, M.C. Pant and D. Parmar, Association of genetic polymorphisms in glutathione S-transferases and susceptibility to head and neck cancer, Mutat Res 638 (2008), 184-194.
11. P.P. Shah, A.P. Singh, M. Singh, N. Mathur, M.C. Pant, B.N. Mishra and D. Parmar, Interaction of cytochrome P4501A1 genotypes with other risk factors and susceptibility to lung cancer, Mutat Res 639 (2008), 1-10.
12. P.P. Shah, A.P. Singh, M. Singh, N. Mathur, B.N.Mishra, M.C. Pant and D. Parmar, Association of functionally important polymorphisms in Cytochrome P4501B1 with lung cancer, Mutat Res 633 (2008), 31-37.
13. D.L. Eaton, E.P. Gallagher, T.K. Bammler and K.L. Kunze, Role of cytochrome P4501A2 in chemical carcinogenesis: implications for human variability in expression and enzyme activity, Pharmacogenetics 5 (1995), 259-274.
14. M.T. Landi, R. Sinha, N.P. Lang and F.F. Kadlubar, Human cytochrome P4501A2, IARC Sci Publ 148 (1999), 179-195.
15. C. Wei, R.J. Caccavale, J.J. Kehoe, P.E. Thomas and M.M. Iba, CYP1A2 is expressed along with CYP1A1 in the human lung, Cancer Lett 171 (2001), 113-120. (Pubitemid 32727362)
16. T. Shimada, H. Yamazaki, M. Mimura, Y. Inui and F.P. Guengerich, Interindividual variations in human liver cytochrome P-450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians, J Pharmacol Exp Ther 270 (1994), 414-423. (Pubitemid 24229655)
17. J. Saruwatari, K.Nakagawa, J. Shindo, T. Tajiri, M. Fujieda, H. Yamazaki, T. Kamataki and T. Ishizaki, A population phenotyping study of three drug-metabolizing enzymes in Kyushu, Japan, with use of the caffeine test, Clin Pharmacol Ther 72 (2002), 200-208. (Pubitemid 35034498)
18. F.P. Guengerich, A. Parikh, R.J. Turesky and P.D. Josephy, Inter-individual differences in the metabolism of environmental toxicants: cytochrome P450 1A2 as a prototype, Mutat Res 428 (1999), 115-124 (Pubitemid 29389684)
19. M.V. Relling, J.S. Lin, G.D. Ayers andW.E. Evans, Racial and gender differences in N-acetyltransferase, xanthine oxidase, and CYP1A2 activities, Clin Pharmacol Ther 52 (1992), 643-658. (Pubitemid 23001871)
20. A. Bartoli, S. Xiaodong, G. Gatti, G. Cipolla, R. Marchiselli and E Perucca, The influence of ethnic factors and gender on CYP1A2-mediated drug disposition: a comparative study in Caucasian and Chinese subjects using phenacetin as a marker substrate, Ther Drug Monit 18 (1996), 586-591. (Pubitemid 26330481)
21. M. Chida, T. Yokoi, T. Fukui, M. Kinoshita, J. Yokota and T. Kamataki, Detection of three genetic polymorphisms in the 5'-flanking region and intron 1 of human CYP1A2 in the Japanese population, Jpn J Cancer Res 90 (1999), 899-902. (Pubitemid 29500425)
22. http://www.cypalleles.ki.se/cyp1a2.htm.
23. http://variantgps.nci.nih.gov/cgfseq/pages/snp500.do.
24. M. Nakajima, T. Yokoi, M. Mizutani, M. Kinoshita, M. Funayama and T. Kamataki, Genetic polymorphism in the 5'- flanking region of humanCYP1A2 gene: effect on theCYP1A2 inducibility in humans, J Biochem 125 (1999), 803-808. (Pubitemid 29192503)
25. S. Pavanello, A. Pulliero, S. Lupi, P. Gregorio and E. Clonfero, Influence of the genetic polymorphism in the 5'-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers, Mutat Res 587 (2005), 59-66. (Pubitemid 41503581)
26. S. Pavanello, F. Bcacute;hir, A. Pulliero, S. Saguem, R. Ben Fraj, A. El Aziz, H.E. Clonfero and G. Mastrangelo, Interaction between CYP1A2-T2467DELT polymorphism and smoking in adenocarcinoma and squamous cell carcinoma of the lung, Lung Cancer 57 (2007), 266-272. (Pubitemid 47285430)
27. F. Gemignani, S. Landi, N. Szeszenia-Dabrowska, D. Zaridze, J. Lissowska, P. Rudnai, E. Fabianova, D. Mates, L. Foretova, V. Janout, V. Bencko, V. Gaborieau, L. Gioia-Patricola, I. Bellini, R. Barale, F. Canzian, J. Hall, P. Boffetta, R.J. Hung and P. Brennan, Development of lung cancer before the age of 50: the role of xenobiotic metabolizing genes, Carcinogenesis 6 (2007), 1287-1293. (Pubitemid 47062689)
28. C. Sachse, J. Brockmoller, S. Bauer and I. Roots, Functional significance of a C-
29. Y. Osawa, K.K. Osawa, A. Miyaishi, M. Higuchi, A. Tsutou, S. Matsumura, Y. Tabuchi, N. Tsubota and J. Takahashi, NAT2 andCYP1A2 polymorphisms and lung cancer risk in relation to smoking status, Asian Pac J Cancer Prev 8 (2007), 103-108.
30. H.L. Chiou, M.F. Wu, W.P. Chien, Y.W. Cheng, R.H. Wong, C.Y. Chen, T.S. Lin and H. Lee, NAT2 fast acetylator genotype is associated with an increased risk of lung cancer among never-smoking women in Taiwan, Cancer Lett 223 (2005), 93-101. (Pubitemid 40693713)
31. S. Zhong, A.F. Howie, B. Ketterer, J. Taylor, J.D. Hayes, G.J. Beckett, C.G.Wathen, C.R.Wolf and N.K. Spurr, Glutathione S-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility, Carcinogenesis 12 (1991), 1533-1537.
32. K. Kawajiri, K. Nakachi, K. Imai, A. Yoshii, N. Shinoda and J.Watanabe, Identification of genetically high risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene, FEBS Lett 263 (1990), 131-133. (Pubitemid 20107795)
33. T. Oyama, T. Mitsudomi, T. Kawamoto, A.Ogami, T.Osaki, Y. Kodama and K. Yasumoto, Detection of CYP1A1 gene polymorphism using designed RFLP and distributions of CYP1A1 genotypes in in Japanese, Int Arch Occup Environ Health 67 (1995), 253-256.
34. http://www.broadinstitute.org/scientific-community/science/ programs/medical-and-population-genetics/haploview/haplo view.
35. E. Aklillu, J.A. Carrillo, E. Makonnen, K. Hellman, M. Pitarque, L. Bertilsson and M. Ingelman-Sundberg, Genetic polymorphism of CYP1A2 in Ethiopians affecting induction and expression: characterization of novel haplotypes with singlenucleotide polymorphisms in intron 1, Mol Pharmacol 64 (2003), 659-669. (Pubitemid 37048569)
36. M.C. Aldrich, S. Selvin, H.M. Hansen, L.F. Barcellos, M.R. Wrensch, J.D. Sison, K.T. Kelsey, P.A. Buffler, C.P. Quesenberry, Jr., M.F. Seldin and J.K. Wiencke, CYP1A1/2 haplotypes and lung cancer and assessment of confounding by population stratification, Cancer Res 69 (2009), 2340-2348.
37. P.P. Shah, K. Saurabh, M.C. Pant, N. Mathur and D. Parmar, Evidence for increased cytochrome P450 1A1 expression in blood lymphocytes of lung cancer, Mutat Res 674 (2009), 74-78.
38. D. Li, L. Jiao, Y. Li,M.A. Doll, D.W. Hein, M.L. Bondy, D.B. Evans, R.A. Wolff, R. Lenzi, P.W. Pisters, J.L. Abbruzzese and M.M. Hassan, Polymorphisms of cytochrome P4501A2 andN-acetyltransferase genes, smoking, and risk of pancreatic cancer, Carcinogenesis 27 (2006), 103-111. (Pubitemid 43025249)
39. P. Bofetta, S.Hecht, N.Grey, P.Gupta andK. Straif, Smokeless tobacco and cancer, Lancet Oncol 9 (2008), 667-675. (Pubitemid 351878052)